Bilastine provides symptom control, improves quality of life in adults with delayed pressure and cholinergic urticaria
A 42-year-old Pakistani female consulted for spontaneously occurring generalized wheals of 6 months duration. She noticed that the wheals mostly appeared on her upper body and were erythematous, painful, pruritic, and unsightly.
Seborrheic dermatitis (SD) is common in Asia, but until now there have not been any standardized clinical diagnostic criteria or any grading system for guiding treatment selection for Asian patients. International guidelines based on Caucasian patients are generally not applicable since there are clinically significant differences in the skin of Asian and Caucasian patients. To address this issue, a consensus group of experts from Asia recently published a new treatment guideline for Asian patients with SD that includes comprehensive treatment algorithms to help physicians select appropriate SD therapies. Dr Wai Kwong Cheong, a specialist in private practice in Singapore, and Dr Ma. Teresita Gabriel from the Research Institute for Tropical Medicine, Muntinlupa City, Philippines, discussed the new guidelines at the 2nd Asia Pacific Meeting of Experts in Dermatology held recently in Hanoi, Vietnam. They highlighted the need to avoid long-term steroid therapy as well as the potential benefits associated with nonsteroidal anti-inflammatory agents with antifungal properties (AIAFp).
Management of acne patients can be challenging due to a dramatic increase in resistance to antibiotics, poor patient compliance due to skin irritation since Asian skin is more prone to irritation, and because of problems associated with dyspigmentation and scarring. Dermocosmetics can be useful adjuvants to pharmacological therapy in this context and a guidebook focusing on their use in Asian patients has recently been released. At the 2nd Asia Pacific Meeting of Experts in Dermatology held recently in Hanoi, Vietnam, Professor Chee Leok Goh from the National Skin Centre, Singapore, and Doctor Su-Ni Wong, a dermatologist in private practice in Singapore, discussed the potential benefit of dermocosmetics such as nicotinamide for acne management and reviewed the recommendations from the recently published guidebook.
The prevalence of atopic dermatitis (AD) has increased significantly over the past decade in Asia highlighting the clear need for non-steroidal options, given the adverse effects associated with long-term use of topical corticosteroids, especially in paediatric patients who may require many years of therapy. At the 2nd Asia Pacific Meeting of Experts in Dermatology held in July 2016 in Hanoi, Vietnam, Dr Mark Tang, a consultant dermatologist at Mt Alvernia Medical Centre in Singapore, discussed the burden of AD in Asia and the important genetic, environmental and peculiar clinical features seen in Asian AD patients. In addition, Dr Leong Kin Fon, a paediatric dermatologist from Kuala Lumpur General Hospital, Malaysia, highlighted the need for nonsteroidal therapies, such as Atopiclair, which has been shown to be a cost-effective option for maintenance treatment of AD patients.
The skin plays an important role as a barrier against external pathogens and any disruption of the biostructural and biochemical dynamics that maintain this barrier function trigger the onset of diseases such as atopic dermatitis. Such disruptions may be caused by both external factors such as food allergies and internal factors such as those that disrupt the creation of the stratum corneum. At the 2nd Asia Pacific Meeting of Experts in Dermatology (APMED) held recently in Hanoi, Vietnam, Associate Professor Maria Victoria Dizon from the University of Santo Tomas, Manila, Philippines, discussed the important role emollients play in maintaining this barrier function, noting that although traditional treatment of diseases such as atopic dermatitis has focused on reducing inflammation at affected sites, patient symptoms may be further improved by using emollients such as MAS063DP (AtopiclairTM, Menarini), which has both anti-inflammatory and barrier repair functions, as add-on therapies.
A 66-year-old Filipino female dressmaker sought consult due to pruritus with the appearance of about less than 20 wheals on both of her forearms and wrists. This condition appeared 2 weeks prior to consult. There was no rapid swelling or angioedema noted and symptoms did not have a pattern.
Current treatment modalities for acne present several challenges including antibiotic resistance. At a recent Menarini-sponsored symposium held during the 2nd Asia Pacific Meeting of Experts in Dermatology (APMED) 2016 in Hanoi, Vietnam, Associate Professor Nopadon Noppakun from the Chulalongkorn University in Bangkok, Thailand discussed the emergence of antibiotic-resistant bacteria and its impact on acne therapy. He also expounded on strategies to minimize antibiotic resistance.
Sebclair’s antifungal and anti-inflammatory activity significantly improves seborrheic dermatitis symptoms
Although topical corticosteroids are effective for the treatment of seborrheic dermatitis, long-term use of these agents is limited by side effects. Moreover, increased understanding of the possible contribution of yeast species to the pathogenesis of the disease suggests that corticosteroids may also be limited by their lack of antifungal efficacy. By contrast, novel nonsteroidal treatments offer great promise. At the 2nd Asia Pacific Meeting of Experts in Dermatology (APMED) held recently in Hanoi, Vietnam, Associate Professor Neal Bhatia, from the Harbor-UCLA Medical Center, Los Angeles, California, US, discussed the potential benefits of new agents such as SebclairTM (Menarini), which combines anti-inflammatory and antifungal properties to effectively treat the symptoms of seborrheic dermatitis.
Bilastine is a novel second-generation antihistamine that optimizes the treatment of chronic urticaria and allergic rhinitis by effectively balancing its symptom-relieving effects with a unique safety profile. At the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress held in Vienna, Austria, Professor Marcus Maurer of the Charité-Universitätsmedizen, Berlin, Germany, and Associate Professor Marysia Recto of the Asian Hospital and Medical Centre, Muntinlupa City, Philippines, outlined bilastine’s effects on patients with chronic urticaria and allergic rhinitis, while Professor Piotr Kuna from the Medical University of Lodz, Poland, described its unique pharmacokinetics. Their presentations highlighted the unique traits that have ensured that bilastine is the only second-generation antihistamine to meet most of the desired features of an ideal drug described by international guidelines such as ARIA (Allergic Rhinitis and its Impact of Asthma), most notably its rapid onset of action and long-lasting effect, which are achieved without sedation.
Renal transplant recipients have a high incidence of hospitalization due to pyelonephritis, according to a Danish population-based cohort study.